Potent antioxidant role of Pirfenidone in experimental cirrhosis

European Journal of Pharmacology

Volumn 595, Issue 1-3, 2008, Pages 69-77

  Salazar Montes, Adriana ^a   Ruiz Corro, Luis ^a   López Reyes, Alberto ^a   Castrejón Gómez, Eugenio ^a   Armendáriz Borunda, Juan ^a,b  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

Experimental liver; Gastrointestinal and urogenital pharmacology; Pirfenidone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON TETRACHLORIDE; CATALASE; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA; DIPHENYLIODONIUM SALT; DRUG VEHICLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIVER ENZYME; PIRFENIDONE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BILE DUCT LIGATION; CELL REGENERATION; COMMON BILE DUCT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FIBROGENESIS; GENE EXPRESSION REGULATION; INFLAMMATION; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ALANINE TRANSAMINASE; ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CARBON TETRACHLORIDE; CATALASE; COLLAGEN TYPE I; COMMON BILE DUCT; HEPATOCYTE GROWTH FACTOR; LIGATION; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALONDIALDEHYDE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; ONIUM COMPOUNDS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDONES; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA;

EID: 52049095251     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.110     Document Type: Article

References (42)

1. Andrews N.C., and Faller D.V. A rapid micropreparation technique for extraction of DNA binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19 (1991) 2499
2. Armendariz-Borunda J., Simkevich C.P., Roy N., Raghow R., Kang A.H., and Seyer J.M. Activation of Ito cells involves regulation of AP-1 binding proteins and induction of type I collagen gene expression. Biochem. J. 304 (1994) 817-824
3. Armendáriz-Borunda J., Islas-Carvajal M., Meza E., Rincón A.R., Alvarez A., Goodman Z.D., Sandoval A.S., Covarrubias A., Aréchiga G., and Garcia L. A pilot study of a novel antiinflamatory and anti-fibrotic agent, Pirfenidone, in patients with liver cirrhosis. Hepatology 38 (2003) 308A
4. Armendáriz-Borunda J., Islas-Carvajal M.C., Meza-García E., Rincón A.R., Sandoval A.S., Salazar A., Berumen J., Alvarez A., Alvarez A., Covarrubias A., Aréchiga G., and García L. A pilot study in cirrhotic patients using a new anti-inflammatory and anti-fibrotic agent, Pirfenidone. Gut. 551 (2006) 663-665
5. Battisti V., Maders L.D., Bagatini M.D., Santos K.F., Spanevello R.M., Maldonado P.A., Brulé A.O., Araújo M.D., Schetinger M.R., and Morsch V.M. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin. Biochem. 41 (2008) 511-518
6. Bonnand A.M., Heathcote E.J., Lindor K.D., and Poupon R.E. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 29 (1999) 39-43
7. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
8. Britton R.S., and Bacon B.R. Intracellular signaling pathways in stellate cell activation. Alcohol. Clin. Exp. Res. 23 (1999) 922-925
9. Bueno R., Daneri A., and Armendariz-Borunda J. Cholestiasis-induced fibrosis is reduced by interferon α-2a and is associated with elevated liver metalloprotease activity. J. Hepatol. 33 (2000) 915-925
10. Burke J.J., and Oliver M.J. Differential temperature sensitivity of pea superoxide dismutases. Plant. Physiol. 100 (1992) 1595-1598
11. Callaway J.K., Beart P.M., and Jarott B. A reliable procedure for comparison of antioxidants in rat brain homogenates. J. Pharmacol. Toxicol. Methods 39 (1998) 155-162
12. Chomzynsky P., and Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-cloroform extraction. Annal. Biochem. 162 (1987) 156-159
13. Flora S.J. Role of free radicals and antioxidants in health and disease. Cell. Mol. Biol. 53 (2007) 1-2
14. Friedman S.L. The cellular basis of hepatic fibrosis. N. Engl. J. Med. 328 (1993) 1828-1835
15. Friedman S.L. Molecular regulation of hepatic fibrosis an integrated cellular response to tissue injury. J. Biol. Chem. 275 (2000) 2247-2250
16. Gancedo M., Ruiz-Corro L., Salazar-Montes A., Rincón A.R., and Armendáriz-Borunda J. Pirfenidone prevents capsular contracture post mammary implantation. Aesthetic. Plast. Surg. 32 (2008) 32-40
17. Garcia L., Hernandez I., Sandoval A., Salazar A., Garcia J., Vera J., Grijalva G., Muriel P., Margolin S., and Armendariz-Borunda J. Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol 37 (2002) 797-805
18. Gaudiot N., Ribiere C., Jaubert A.M., and Giudicelli Y. Endogenous nitric oxide is implicated in the regulation of lipolysis through antioxidant related effect. Am. J. Physiol. 279 (2000) 1603-1610
19. Giri S.N., Leonard S., Shi X., Margolin S.B., and Vallyathan V. Effect of Pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Pathol. Toxicol. Oncol. 18 (1999) 169-177
20. http://dna-9.int-med.uiowa.edu/RealtimePCRdocs/Bulletin 2 Applied Byosistem.
21. Iyer S.N., Gurujeyalakshmi G., and Giri S.N. Effects of pìrfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther 291 (1999) 367-373
22. Kono H., Rusyn I., Uesugi T., Yamashina S., Connor H., Dikalova A., Mason R., and Thurman R. Diphenyleneiodonium sulfate, an NADPH oxidase inhibitor, prevents early alcohol-induced liver injury in the rat. Am. J. Physiol. Gastrointest. Liver. Physiol. 280 (2001) G1005-G1012
23. Li Y., and Trush M.A. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem. Biophys. Res. Commun. 253 (1998) 295-299
24. Manchenko G.P. Handbook of Detection of Enzymes on Electrophoretic Gels (1994), CRC Press 92
25. Nakanishi H., Kaibori M., Teshima S., Yoshida H., Kwon A.H., Kamiyama Y., Nishizawa M., Ito S., and Okumura T. Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1 beta at a step of NF-kappa B DNA binding in hepatocytes. J. Hepatol. 41 (2004) 730-736
26. Oh I., Ozaki K., Sato K., Meguro R., Tatara R., Hatanaka K., Nagai T., Muroi K., and Ozawa K. Interferon g and NF-κB mediate nitric oxide production by mesenchymal stromal cells. Biochem. Biophys. Res. Commun. 355 (2007) 956-962
27. Pinzani M. Therapies for hepatic fibrosis: real hope or just academic exercise? Dig. Liver. Dis 36 (2004) 714-716
28. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol. Aspects. Med. 21 (2000) 49-98
29. Requena J.R., Fu M.X., Ahmed M.U., Jenkins A.J., Lyons T.J., Baynes J.W., and Thorpe S.R. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem. J. 322 (1997) 317-325
30. Salgado S., García J., Vera J., Siller F., Bueno M., Miranda A., and Armendáriz-Borunda J. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol. Ther. 2 (2000) 545-551
31. Schoedel K.E., Tyner V.Z., Kim T.H., Michalopoulos G.K., and Mars W.M. HGF, met and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Mod. Pathol. 16 (2003) 14-21
32. Schwart D., Mendonca M., Schwartz I., Xia Y., Satriano J., Wilson C., and Blantz R. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J. Clin. Invest. 100 (1997) 439-448
33. Shimizu T., Kuroda T., Hata S., Fukagawa M., Margolin S.B., and Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 54 (1998) 99-109
34. Shiota G., Kunisada T., Oyama K., Udagawa A., Nomi T., Tanaka K., Tsutsumi A., Isono M., Nakamura T., Hamada H., Sakatani T., Sell S., Sato K., Ito H., and Kawasaki H. In vivo transfer of hepatocyte growth factor gene accelerate proliferation oval cells in a 2-acetylaminofluorene/partial hepatectomy model rats. FEBS Lett. 470 (2000) 325-330
35. Sokol R.J. Liver cell injury and fibrosis. J. Pediatr. Gastroenterol. Nutr. 35 (2002) 7-10
36. Sokol R., Straka M., Dahl R., Devereaux M.W., Verushalmi B., Gumpricht E., Elkins N., and Everson G. Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids. Pediatr. Res. 49 (2001) 519-531
37. Tada S., Nakamuta M., and Enjoji M. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. 28 (2001) 522-527
38. Tapia G., Pepper I., Smok G., and Videla L.A. Kupffer cell function in thyroid hormone induced liver oxidative stress in the rat. Free Rad. Res 26 (1997) 267-279
39. Tsukamoto H., Rippe R., Niemela O., and Lin M. Roles of oxidative stress in activation of Kupffer and Ito cells in liver fibrogenesis. J. Gastroenterol. Hepatol. 10 (1995) S50-S53
40. Vrba J., and Mondriasky M. Oxidative burst of Kupffer cells: target for liver injury treatment. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 146 (2002) 15-20
41. Wang T., Sun N.L., Zhang W.D., Li H.L., Lu G.C., Yuan B.J., Jiang H., She J.H., and Zhang C. Protective effects of dehydrocavidine on carbon tetrachloride-induced acute hepatotoxicity in rats. J. Ethnopharmacol. 117 (2008) 300-308
42. Wheeler M.D., Kono H., Rusyn I., Arteel G.E., McCarty D., Samuliski R.J., and Thurman R. Chronic ethanol increases adeno-associated viral transgene expression in rat liver via oxidant and NFκB-dependent mechanisms. Hepatology 32 (2000) 1050-1059